Vincristine neuropathy. Clinical and electrophysiological observations.
D000200:Action Potentials; D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008475:Median Nerve / Q000503:physiopathology; D008875:Middle Aged; D009046:Motor Neurons / Q000502:physiology; D009431:Neural Conduction; D010243:Paralysis / Q000139:chemically induced / Q000209:etiology; D010525:Peripheral Nerves / Q000503:physiopathology*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000503:physiopathology; D012023:Reflex, Monosynaptic / Q000187:drug effects; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D014750:Vincristine